Clinical Trials - Physician

Clinical Trials - Physician

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer(S1802) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer (GI002) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Disease Registry for patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) (INFORM CLL) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated NonSmall Cell Lung Cancer (LUNGMAP)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Multi-Center, Open Label, Phase II Trial to Assess the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab in Participants with Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent (LEAP-004) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Multicenter, Open-label, Randomized Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First- Line Treatment of Subjects with Advanced Renal Cell Carcinoma (16145) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Multicenter, Randomized, Double-blind, Placebo-Controlled Study of Ibrutinib in Combination with Rituximab vs Placebo in Combination with Rituximab in Treatment Naive Subjects with Follicular Lymphoma(PERSPECTIVE) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Multicenter, Randomized, Open-label Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338- 063) (16238) III
Mary Beth WIlwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Phase I Study of CDX-1140, a Fully Human Agonist Anti-CD40 Monoclonal Antibody as Monotherapy or in Combination in Patients with Advanced Solid Tumors (CDX1140-01) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Phase I Study of the Hightly Selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer, NonSmall Cell Lung Cancer, and Other Advanced Solid Tumors (BLU-667-1101) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Phase I Study of the Hightly Selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer, NonSmall Cell Lung Cancer, and Other Advanced Solid Tumors (BLU-667-1101) (18164) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Phase I Study of the Hightly Selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer, NonSmall Cell Lung Cancer, and Other Advanced Solid Tumors (BLU-667-1101) (18164)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Phase II Study of Olaparib Monotherapy in Participants with Previously Treated, HomologousRecombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (LYNK-002) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Pilot Study of Chemotherapy Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients (228-17) III
Mary Beth Wilwerding
Phone
402-991-8070
Fax
402-991-8850
A Placebo Controlled Study to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention vs Early Treatment Approaches (A221701) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Placebo Controlled Trial of Adjuvant MK3475 in RCC Post Nephrectomy (MK3475-564) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Prospective Multicenter Non-interventional Study of Patients Receiving Palbociclib in Advanced Breast Cancer (Polaris) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients wtih Metastatic Castration-Resistant Prostate Cancer (13Y-MC-JPCM) (18128) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib, Crizotinib, Savolitinib, and Sunitinib) in Metastatic Papillary Renal Carcinoma (S1500) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Open Label Study of Brigatinib vs Alectinib in Advanced Anaplastic Lymphoma Kinase Positive Non Small Cell Lung Cancer Patients Who Have Progressed on Crizotinib (18129) (Brigatinib-3001) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study Comparing PDR001, Debrafenib and Trametinib vs Placebo, Dabrafenib and Trametinib in Previously Untreated Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma (CPDR001F2301) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study Evaluating the Efficacy and Safety of Canakinumab vs Placebo as Adjuvant Therapy in Subjects with Stages II-IIIA and IIIB Completely Resected NonSmall Cell Lung Cancer (17167) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study of Adjuvant vs NeoAdjuvant Pembrolizumab for Clinically Detectable Stage III-IV High Risk Melanoma (S1801) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study of Atezolizumab vs Placebo administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab for Patients with Newly Diagnosed Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (GOG3015) (YO39523) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study of Nivolumab with Ipilimumab or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1/L1 Agent (S1616) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members